Anti–PD-1 and CTLA-4 Bispecific Antibody Cadonilimab Monotherapy for Previously Treated Advanced NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Lung Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study)
Lung Cancer 2023 Aug 29;184(xx)107355, Y Zhao, Y Ma, Y Fan, J Zhou, N Yang, Q Yu, W Zhuang, W Song, ZM Wang, B Li, Y Xia, H Zhao, L ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.